No abstract

No abstract

No abstract

4‐Hydrazinothieno[2,3‐d]pyrimidines were cyclized with triethyl orthoformate and formic acid to give 1,2,4‐triazolo[4,3‐c]thieno[3,2‐e]pyrimidines and 1,2,4‐triazolo[2,3‐c]thieno[3,2‐e]pyrimidines depending on the reaction conditions employed.

No abstract

Alzheimer's disease (AD) is a progressive neurodegenerative disorder leading to irreversible loss of neurons, cognition and formation of abnormal protein aggregates. Rivastigmine, a reversible cholinesterase inhibitor used for the treatment of AD, undergoes extensive first-pass metabolism, thus limiting its absolute bioavailability to only 36% after 3-mg dose. Due to extreme aqueous solubility, rivastigmine shows poor penetration and lesser concentration in the brain thus requiring frequent oral dosing. This investigation was aimed to formulate microemulsion (ME) and mucoadhesive microemulsions (MMEs) of rivastigmine for nose to brain delivery and to compare percentage drug diffused for both systems using in-vitro and ex-vivo study. Rivastigmine-loaded ME and MMEs were prepared by titration method and characterized for drug content, globule size distribution, zeta potential, pH, viscosity and nasal ciliotoxicity study. Rivastigmine-loaded ME system containing 8% w/w Capmul MCM EP, 44% w/w Labrasol:Transcutol-P (1:1) and 48% w/w distilled water was formulated, whereas 0.3% w/ w chitosan (CH) and cetyl trimethyl ammonium bromide (as mucoadhesive agents) were used to formulate MMEs, respectively. ME and MMEs formulations were transparent with drug content, globule size and zeta potential in the range of 98.59% to 99.43%, 53.8 nm to 55.4 nm and À2.73 mV to 6.52 mV, respectively. MME containing 0.3% w/w CH followed Higuchi model (r 2 ¼ 0.9773) and showed highest diffusion coefficient. It was free from nasal ciliotoxicity and stable for three months. However, the potential of developed CH-based MME for nose to brain delivery of rivastigmine can only be established after in-vivo and biodistribution study.

A variety of novel 2,4‐diaminothieno[2,3‐d]pyrimidines has been prepared through the reduction of the corresponding azido/tetrazolothienopyrimidines under acidic conditions.

No abstract